Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76,572 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients.
Zazuli Z, Otten LS, Drögemöller BI, Medeiros M, Monzon JG, Wright GEB, Kollmannsberger CK, Bedard PL, Chen Z, Gelmon KA, McGoldrick N, Kitchlu A, Vijverberg SJH, Masereeuw R, Ross CJD, Liu G, Carleton BC, Maitland-van der Zee AH. Zazuli Z, et al. Among authors: chen z. Genes (Basel). 2019 May 10;10(5):364. doi: 10.3390/genes10050364. Genes (Basel). 2019. PMID: 31083486 Free PMC article.
Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.
Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC. Drögemöller BI, et al. Among authors: chen z. JAMA Oncol. 2017 Nov 1;3(11):1558-1562. doi: 10.1001/jamaoncol.2017.0502. JAMA Oncol. 2017. PMID: 28448657 Free PMC article.
A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).
Chiu JW, Hotte SJ, Kollmannsberger CK, Renouf DJ, Cescon DW, Hedley D, Chow S, Moscow J, Chen Z, Perry M, Diaz-Padilla I, Tan D, Hirte H, McWhirter E, Chen H, Siu LL, Bedard PL. Chiu JW, et al. Among authors: chen z, chen h. Invest New Drugs. 2016 Feb;34(1):104-11. doi: 10.1007/s10637-015-0313-8. Epub 2015 Dec 19. Invest New Drugs. 2016. PMID: 26686201 Free PMC article. Clinical Trial.
Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome.
Korpanty GJ, Eng L, Qiu X, Faluyi OO, Renouf DJ, Cheng D, Patel D, Chen Z, Tse BC, Knox JJ, Dodbiba L, Teichman J, Azad AK, Wong R, Darling G, Reisman D, Cuffe S, Liu G, Xu W. Korpanty GJ, et al. Among authors: chen z. Oncotarget. 2017 Apr 25;8(17):28093-28100. doi: 10.18632/oncotarget.15890. Oncotarget. 2017. PMID: 28427211 Free PMC article.
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
Richter S, Bedard PL, Chen EX, Clarke BA, Tran B, Hotte SJ, Stathis A, Hirte HW, Razak AR, Reedijk M, Chen Z, Cohen B, Zhang WJ, Wang L, Ivy SP, Moore MJ, Oza AM, Siu LL, McWhirter E. Richter S, et al. Among authors: chen z, chen ex. Invest New Drugs. 2014 Apr;32(2):243-9. doi: 10.1007/s10637-013-9965-4. Epub 2013 May 5. Invest New Drugs. 2014. PMID: 23645447 Free PMC article. Clinical Trial.
ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.
Cuffe S, Azad AK, Qiu X, Qiu X, Brhane Y, Kuang Q, Marsh S, Savas S, Chen Z, Cheng D, Leighl NB, Goss G, Laurie SA, Seymour L, Bradbury PA, Shepherd FA, Tsao MS, Chen BE, Xu W, Liu G. Cuffe S, et al. Among authors: chen z, chen be. Cancer Epidemiol. 2016 Apr;41:50-6. doi: 10.1016/j.canep.2015.12.012. Epub 2016 Jan 24. Cancer Epidemiol. 2016. PMID: 26816351
Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers.
Wong KM, Qiu X, Cheng D, Azad AK, Habbous S, Palepu P, Mirshams M, Patel D, Chen Z, Roberts H, Knox J, Marquez S, Wong R, Darling G, Waldron J, Goldstein D, Leighl N, Shepherd FA, Tsao M, Der S, Reisman D, Liu G. Wong KM, et al. Among authors: chen z. Cancer Med. 2014 Apr;3(2):426-33. doi: 10.1002/cam4.201. Epub 2014 Feb 12. Cancer Med. 2014. PMID: 24519853 Free PMC article.
BRM polymorphisms, pancreatic cancer risk and survival.
Segedi M, Anderson LN, Espin-Garcia O, Borgida A, Bianco T, Cheng D, Chen Z, Patel D, Brown MC, Xu W, Reisman D, Gallinger S, Cotterchio M, Hung R, Liu G, Cleary SP. Segedi M, et al. Among authors: chen z. Int J Cancer. 2016 Dec 1;139(11):2474-81. doi: 10.1002/ijc.30369. Epub 2016 Aug 18. Int J Cancer. 2016. PMID: 27487558
BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.
Liu G, Cuffe S, Liang S, Azad AK, Cheng L, Brhane Y, Qiu X, Cescon DW, Bruce J, Chen Z, Cheng D, Patel D, Tse BC, Laurie SA, Goss G, Leighl NB, Hung R, Bradbury PA, Seymour L, Shepherd FA, Tsao MS, Chen BE, Xu W, Reisman DN. Liu G, et al. Among authors: chen z, chen be. Clin Cancer Res. 2017 May 15;23(10):2460-2470. doi: 10.1158/1078-0432.CCR-16-1640. Epub 2016 Nov 8. Clin Cancer Res. 2017. PMID: 27827316 Free PMC article. Clinical Trial.
76,572 results
You have reached the last available page of results. Please see the User Guide for more information.